Evaxion Biotech A/S (NASDAQ:EVAX) Short Interest Down 12.8% in November

Evaxion Biotech A/S (NASDAQ:EVAX) saw a large drop in short interest in November. As of November 30th, there was short interest totalling 31,400 shares, a drop of 12.8% from the November 15th total of 36,000 shares. Based on an average daily volume of 54,200 shares, the short-interest ratio is currently 0.6 days.

Evaxion Biotech A/S Trading Down 5.7 %

Shares of EVAX stock traded down $0.06 during trading on Tuesday, hitting $0.99. 145,139 shares of the stock traded hands, compared to its average volume of 209,070. The firm has a market capitalization of $5.81 million, a P/E ratio of -3.24 and a beta of -0.39. The company has a debt-to-equity ratio of 7.99, a current ratio of 1.00 and a quick ratio of 2.80. Evaxion Biotech A/S has a 52-week low of $0.91 and a 52-week high of $13.61. The firm’s fifty day moving average price is $2.08 and its 200-day moving average price is $2.70.

Evaxion Biotech A/S (NASDAQ:EVAX) last announced its earnings results on Thursday, October 31st. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.08. The firm had revenue of $3.02 million during the quarter, compared to analysts’ expectations of $0.19 million. As a group, research analysts forecast that Evaxion Biotech A/S will post -0.15 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $14.00 price target on shares of Evaxion Biotech A/S in a research report on Friday, November 1st.

Institutional Investors Weigh In On Evaxion Biotech A/S

An institutional investor recently bought a new position in Evaxion Biotech A/S stock. Invst LLC bought a new stake in Evaxion Biotech A/S (NASDAQ:EVAX) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 54,000 shares of the company’s stock, valued at approximately $156,000. Invst LLC owned approximately 1.00% of Evaxion Biotech A/S as of its most recent SEC filing. Institutional investors own 11.04% of the company’s stock.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.